Further functional studies of the COL4A3/COL4A4 mutations and application of in vitro and/or in vivo models with genetic deficiency are warranted to facilitate a better understanding of the pathogenesis and development of effective treatments for collagen IV nephropathies. This evidence concerns the gene COL4A3 and Nephropathy.